Literature DB >> 23082975

Rational drug design: the search for Ras protein hydrolysis intermediate conformation inhibitors with both affinity and specificity.

Xiliang Zheng1, Zuojia Liu, Dan Li, Erkang Wang, Jin Wang.   

Abstract

Computer-aided drug design (CADD) plays significant roles in all stages of today's drug discovery. Many CADD technologies and methods were employed in finding promising hits against different targets during the past several decades. In this review, the most common molecular modeling methods applied to computer-aided drug design are discussed. However, how to effectively integrate these computational methods and then combine them with experiments to improve the hit rate is still a challenge. In addition, the present study reviews the ISR (intrinsic specificity ratio) as a novel concept and quantitative criterion for binding specificity to be applied as a complement in addition to binding affinity for finding new leads. Using Ras protein as a case study, Molecular modeling calculations and the subsequent biological testings for the hits are performed, the specificity of these hits is also studies against the normal and cancer cells aiming at discovering the novel chemical compounds with minimal side effects. Herein, the case study also includes the evaluations for tumor-specific cytotoxicity on different cell lines. The current results suggest that ISR is useful for quantitative assessment of specificity of small molecules.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23082975     DOI: 10.2174/1381612811319120012

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  9 in total

Review 1.  Pocket-based drug design: exploring pocket space.

Authors:  Xiliang Zheng; Linfeng Gan; Erkang Wang; Jin Wang
Journal:  AAPS J       Date:  2012-11-22       Impact factor: 4.009

Review 2.  Perspectives on the landscape and flux theory for describing emergent behaviors of the biological systems.

Authors:  Jin Wang
Journal:  J Biol Phys       Date:  2021-11-25       Impact factor: 1.365

3.  Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras.

Authors:  Priyanka Prakash; Alemayehu A Gorfe
Journal:  Mol Simul       Date:  2014-03-19       Impact factor: 2.178

4.  Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer.

Authors:  Xiaoyu Guo; Wenjing Zhao; Zuojia Liu; Jin Wang
Journal:  Oncotarget       Date:  2018-01-08

5.  Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration.

Authors:  Yongliang Yang; Guohui Li; Dongyu Zhao; Haoyang Yu; Xiliang Zheng; Xiangda Peng; Xiaoe Zhang; Ting Fu; Xiaoqing Hu; Mingshan Niu; Xuefei Ji; Libo Zou; Jin Wang
Journal:  Chem Sci       Date:  2015-01-13       Impact factor: 9.825

6.  Uncovering the molecular and physiological processes of anticancer leads binding human serum albumin: A physical insight into drug efficacy.

Authors:  Chuanbo Liu; Zuojia Liu; Jin Wang
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

7.  Discovery of novel inhibitors of human S-adenosylmethionine decarboxylase based on in silico high-throughput screening and a non-radioactive enzymatic assay.

Authors:  Chenzeng Liao; Yanlin Wang; Xiao Tan; Lidan Sun; Sen Liu
Journal:  Sci Rep       Date:  2015-06-01       Impact factor: 4.379

8.  Small Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK Signaling.

Authors:  Na Guo; Zuojia Liu; Wenjing Zhao; Erkang Wang; Jin Wang
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

9.  Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer.

Authors:  Jiaxin Zhang; Zuojia Liu; Wenjing Zhao; Xunzhe Yin; Xiliang Zheng; Chuanbo Liu; Jin Wang; Erkang Wang
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.